Authors concluded that all three assays — Oncotype DX, EndoPredict, and Prosigna — met Canadian thresholds for cost-effectiveness and urged caution in considering the findings.
As expected, the UK's Competition and Markets Authority is referring the proposed Illumina acquisition of PacBio for an in-depth Phase 2 investigation.
iCubate said that it now has a comprehensive solution within European markets for the detection of bloodstream bacteria and important resistance markers.
Science Takes a Look at Genetic Regulation of Gene Expression in During Cellular Differentiation and More
In Science this week: hundreds of eQTLs change during cellular differentiation, goldfish genome, and more.
The suits, targeting products that include the BGISEQ-500 and MGISEQ-2000 platforms, add fuel to the ongoing patent dispute between the two firms.
The Frederick, Maryland-based firm has received regulatory clearance for a multiplexed array-based assay after more than 15 years in development.
The firms aim to combine PerkinElmer 's Ordered Data Interpretation Network and FDNA's Face2Gene facial analysis software to target emerging markets.
Researchers analyzed RNA sequencing data gathered from induced pluripotent stem cells as they differentiated into heart muscle cells.
23andMe has launched a new genetic health risk report for MUTYH-Associated Polyposis (MAP), one of three main hereditary colorectal cancer syndromes. According to the firm, the report examines two genetic variants in the MUTYH gene, Y179C and G396D, associated with MAP. The firm will offer the report to new Health + Ancestry Service customers as well as existing 23andMe Health + Ancestry Service customers genotyped on its most recent platforms.
Co-Diagnostics have appointed Eugene Durenard and Ted Murphy to its board of directors, and will serve on the board's compensation and corporate governance/nomination committees and audit committees as independent directors. The two new members will be replacing Frank Kiesnar, who resigned as director of the firm, and Edward Borkowski, who retired as a director of the firm.
Durenard has been founder and CEO of Hyperbolic Holdings since 2018, co-founder and chief innovation officer of Healthcare Impact Holdings since May 2018, co-founder and trustee of Healthcare Impact Foundation since 2017, co-founder of Global Better Health since December 2018, as well as advisor and managing director of the Stetson Family Office since September 2016.
Murphy serves on the board of directors of three Canadian publicly reporting companies, as well as a senior partner in a private investment firm since 1999.
BillionToOne has commercially launched its Unity prenatal screening assay. According to BillionToOne, the assay is powered by its molecular counting technology and is the only prenatal screen that tests cell-free fetal DNA for cystic fibrosis, spinal muscular atrophy, and sickle cell disease using only one tube of the mother's blood. The firm said it will make the test available at select clinics through its early access program, with plans for a broader commercial launch later this year.
The partnership will make public and custom transcriptomic datasets available directly through Genestack's recently introduced Omics Data Manager system.
By analyzing thousands of cancer genomes, investigators identified hotspots for passenger mutations at DNA hairpin sites that are a preferred substrate for APOBEC, a cytidine deaminase.
Regulators in the country granted additional approval of the test as a companion diagnostic for Rozlytrek, marketed in Japan by Roche's Chugai Pharmaceutical.
Researchers tracked down monogenic risk variants, carriers, disease culprits, and more for 50 individuals with cardiomyopathy and 50 unaffected participants.
A lawsuit alleges the University of Chicago shared medical record data with Google that included information that should not have been, according to the New York Times.